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1. Introduction 
Type 1 diabetes (T1D), also known as Insulin dependent diabetes mellitus (IDDM) is an 
incurable multi-factorial autoimmune disorder. The disease is characterized by the loss of 
insulin producing beta cells of the pancreas resulting in abnormal metabolism of glucose 
which may lead to ketoacidosis and several other complications like retinopathy, 
nephropathy and even cardio-vascular diseases and pre-mature deaths (Pociot & 
Mcdermott, 2002). World-wide disease affects 1 in 300-400 children (Todd, 1995). Population 
based data from South India shows the incidence of T1D for four year period to be 
10.5/100,000/ year (Ramachandran et al., 1996). Similar prevalence of type 1 diabetes has 
been observed in North India. A study from district of Karnal in North India reported the 
prevalence to be 10.20/100,000 population, with a higher prevalence in urban (26.6/100,000) 
as compared to rural areas (4.27/100,000) (Kalra et al. 2010). T1D develops as a result of 
complex interaction of many genetic and environmental factors leading to autoimmune 
destruction of the insulin producing pancreatic beta cells. While 20 genomic intervals have 
been implicated for the manifestation of the disease (Pociot & Mcdermott, 2002), role of an 
intricate network of the products of these genes cannot be ruled out. However, unravelling 
different factors involved and how they interact in integrated networks is like solving a jig-
saw puzzle which is the aim of our studies. Basic problem with T1D patients is that by the 
time they first report to the physician, most of their pancreatic beta cells are already 
destroyed which leaves the clinicain with no option but to give daily insulin injections. So, 
there is a need to identify the prediabetics before the onset of the disease and device ways to 
inhibit autoimmunity in them. Following sections will show the work done in our 
laboratory to understand the intricate networks in which the genes involved in immune 
responses interact and their implications.  
2. Role of Major Histocompatibility Complex (IDDM1) 
The Major Histocompatibility Complex (MHC) region on chromosome 6p21.31 has been 
shown to have major role in predisposition to get type 1 diabetes. It is also called  IDDM1. 
2.1 Genes and proteins of the Major Histocompatibility Complex (MHC) 
The human MHC, Human Leukocyte Antigen (HLA) system is the most polymorphic system 
of the human genome with more than 5000 alleles. The alleles of HLA loci are co-dominant i.e. 
both the alleles at a particular locus are equally expressed. The genes of HLA code for 
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glycoprotein molecules which are expressed on nucleated cells and are responsible for the 
recognition of non-self from self. The function of MHC molecules is to present exogenous and 
endogenous antigens in the form of peptides to the T cells for subsequent immune response to 
take place. The gene map of the MHC region of man on chromosome 6p21.3 shows that it 
spans about 4 megabases (3,838,986 bp to be precise). It is the most gene-dense region of the 
human genome with 224 genes of which 128 are known to be expressed. 40% of the expressed 
genes in this region have immune related functions (Horton et al., 2004). 
There are two types of MHC molecules : MHC Class-I and Class-II which differ from each 
other in their constituents as well as their functions.  
2.1.1 MHC class-I genes and proteins 
MHC class-I genes are expressed on all nucleated cells in the form of cell surface 
glycoproteins. Function of MHC class-I molecules is to present antigenic peptides to CD8+ 
cytotoxic T cells (CTLs). The classical class-I genes in humans are HLA-A, HLA-B and HLA-
C. All these genes are very polymorphic with 1519 alleles for HLA-A locus, 2069 alleles for 
B-locus and 1016 alleles for C-locus and these numbers are increasing with the discovery of 
new alleles everyday.  
The MHC class-I molecule is a hetero-dimer of a heavy alpha chain (about 40-45 KDa) and 
the light chain, beta 2 microglobulin (β2m) of 12 KDa (Bjorkman et al., 1987). While the genes 
for the heavy chains i.e. the alpha chains are encoded on chromosome 6, the gene for β2m is 
encoded on human chromosome 15. The alpha chain of the MHC class-I molecule has three 
domains alpha 1 (α1), alpha 2 (α2)and alpha 3 (α3). Alpha 1 (α1) and alpha 2  (α2) domains 
are the most polymorphic domains since they constitute the peptide binding groove of the 
MHC molecule. The genes encoding MHC class-I alpha chain  have 8 exons with  second 
and the third exons of the alpha chain gene being most polymorphic since they code for  the 
α1 and α2 domains. The peptides that are presented by the MHC molecules have allele 
specific motifs, which means that certain peptides can be presented by certain MHC 
molecules. The affinity of the peptide to bind to the peptide binding groove is  determined 
by the anchors present on the peptide binding groove where the peptides go and bind 
through hydrogen bonds. Specific motifs on the peptides determine which peptides would 
bind to which MHC molecule (Falk et al., 1991, Garrett et al., 1989). 
2.1.2 MHC class-II genes and proteins 
MHC class-II glycoproteins in humans are HLA-DR, -DP and –DQ. The MHC class-II 
molecule is a heterodimer of two polypeptide chains: an alpha (25-33 KDa)  and a beta chain 
(24-29KDa) (Brown et al., 1993, De Vries & Van Rood, 1985). Unlike MHC class-I, both alpha 
and beta chains of the class-II molecule are encoded on chromosome 6. DRB1 gene encodes 
DR beta chain while DRA1 encodes DR alpha chain with 966 DRB1 alleles and 3 DRA1 
alleles. Similarly DQB1 and DPB1 encode beta chains of DQ and DP molecules with 144 and 
145 alleles respectively and DQA1 and DPA1 encode the alpha chains of DQ and DP 
molecules with 35 and 28 alleles respectively (Robinson et al., 2009).  
While HLA class-I molecules are expressed on all nucleated cells, HLA class-II molecules are 
expressed on antigen presenting cells like macrophages, dendritic cells, B cells, thymic 
epithelium and activated T cells (Holling et al., 2004). The function of MHC class-II 
molecules is to present antigenic peptides to the CD4+ T helper cells (Th cells) which in turn 
initiate a cascade of immunological events resulting in activation of CD8+ cytotoxic T cells 
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(Horton et al., 2004). When a non-self antigen is presented to CD4+ T helper cells, they get 
activated and secrete certain cytokines like Interferon gamma and TNF-alpha in case of Th1 
cells and IL-4, IL-5 and/or IL-6 in case of Th2 cells. While the cytokines secreted by Th1 cells 
activate the cytotoxic T cells which have already seen the antigen in the context of HLA 
class-I, Th2 cytokines activate the B cells to become plasma cells which make the antibodies 
against antigen they have seen. Thus an immune response takes place which varies in 
strength depending on the host factors and the peptides being presented. 
There are about 50,000-100,000 MHC molecules on each cell. Most MHC molecules are 
occupied by self peptides and the T cells are tolerized against them during thymic education 
so that auto-immune responses do not take place, however, some times something goes 
awry and there is a break in the tolerance resulting in recognition of self as non-self by the 
immune system resulting in an auto-immune response. This could be due to low expression 
of some antigens in the thymus which may result in self-reactive T cells to reach the 
peripheral circulation. Or it could be due to escape of self-reactive T cells from clonal 
deletion during T cell development. 
2.2 MHC and Type 1 diabetes 
Despite so much polymorphism, significant increase of one or more alleles of HLA in a 
disease population as compared to healthy controls, suggests functional implications due to 
their role in antigen presentation. We observed a significant increase of DRB1*03:01 (p<10-6, 
Odds Ratio (OR) =11.0), DRB1*04:01 (p<0.01, OR=6.4) and DRB1*04:05 (p<0.03, OR=5) in the 
patients (Figure 1a) using high resolution typing method of polymerase chain reaction 
followed by hybridization with sequence specific oligonucleotide probes(PCR-SSOP) (Rani 
et al., 2004, Rani et al., 1999).  
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Fig. 1. Distribution of HLA-DRB1 alleles significantly increased in Type 1 diabetes. a. 
DRB1*03:01, DRB1*04:01, DRB1*04:05 showing significant increase and DRB1*04:03, 
DRB1*04:04 and DRB1*07:01 showing significant reduction in T1D patients as compared to 
healthy controls. b. shows the homozygosity and heterozygosity of predisposing and 
protective alleles significantly increased or reduced in the T1D patients. Homozygous 
DRB1*03:01/03:01, heterozygous DRB1*03:01/04:05, DRB1*03:01/04:01 and DRB1*03:01/X 
were significantly increased and DRB1*04:03/X and DRB1*07:01 X were significantly 
reduced in the T1D patients as compared to controls. 
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Our results were in concordance with earlier studies in North Indians (Gupta et al., 1991, 
Kanga et al., 2004, Mehra et al., 2002, Sanjeevi et al., 1999, Witt et al., 2002). However, we 
also observed DRB1*07:01(p<7x10-6, OR= 0.16), DRB1*04:03 (p< 0.02, OR=0.25) and 
DRB1*04:04 (p< 0.05, OR= 0.2) to be significantly decreased in the patients as compared to 
controls. We did not find any significant reduction of HLA-DR2 haplotype DRB1*15:01-
DQB1*06:02 which has been shown to confer strong protection from T1D in most ethnic 
groups (Baisch et al., 1990, Pugliese et al., 1995), probably because this haplotype has been 
found with a low frequency of only 1.06% in North Indians (Rani et al., 1998). On the other 
hand, we observed a marginally reduced frequency of DRB1*15:06 in patients as compared 
to controls, which did not remain significant when p was corrected for the number of alleles 
tested for DRB1 locus (Rani et al., 2004).  
Figure 1b shows the homozygosity and heterozygosity of DRB1*03:01 and DRB1*04 alleles 
significantly increased in T1D. Homozygous DRB1*03:01 (p<10-7, OR=14.54), heterozygous 
DRB1*03:01/*04:05 (p<0.03, OR =10.9) and DRB1*03:01/*04:01 (p<0.01, OR = 13) were 
significantly increased in the patients as compared to controls who lacked this heterozygous 
combination. Heterozygous 03:01/X (i.e. any other allele) (p<0.04, OR = 1.89) was also 
significantly increased in the patients as compared to controls.  Heterozygous DRB1*04:03/X 
(p<0.04, OR = 0.22) and DRB1*07:01/X (p < 10-7, OR = 0.066) were significantly reduced in 
the T1D patients as compared to controls suggesting their protective role. Significant 
protection has been shown to be associated with DRB1*04:03 allele in a Belgian study of 
diabetes (Van Der Auwera et al., 1995).  DRB1*03:01, DRB1*04:01 and DRB1*04:05 have also 
been shown to be associated with T1D patients in Sardinians, black population from 
Zimbabwe, Lithuanians, Czecks, Lebanese, Brazilians and African Americans (Alves et al., 
2009, Cucca et al., 1995, Ei Wafai et al., , Fernandez-Vina et al., 1993, Garcia-Pacheco et al., 
1992, Skrodeniene et al., , Tait et al., 1995, Weber et al.).  
Cucca et al suggested that amino acid position 74 and 86 in DR beta chain are the key 
residues in the P4 and P1 pockets of the peptide binding groove of HLA-DR molecules 
(Cucca et al., 2001).  A combined presence of Asp, Glu and Val in positions 57 (P9), 74 (P4) 
and 86 (P1) in protective DRB1*04:03 has been shown to be different from high risk 
DRB1*04:05 which has Ser, Ala and Gly at these positions. However, in the North Indians 
we observed DRB1*03:01 to be at highest risk and this allele has Asp, Arg, and Val in the 
three positions (Figure 2). A less predisposing allele in North Indians, DRB1*04:01 has Asp, 
Ala, Gly and the protective DRB1*04:04 and DRB1*07:01 have Asp, Ala, Val and Val, Gln 
and Gly in the three positions respectively. Thus, Asp, Arg and Val in DRB1*03:01 is entirely 
different from Val, Gln, and Gly in DRB1*07:01 which seems to be important in our study 
since all the four DR4 alleles are present in less than 10% of the patients or control samples. 
In essence, these data suggest that it is probably not 74 and 86 alone, rather an integration 
of all the pockets of the peptide binding groove that determines which peptide of an auto-
antigen would bind to the MHC molecule and result in auto-aggression based on the thymic 
education. 
We also studied the alleles of DQB1 locus. DQB1*02:01 which is linked to DRB1*03:01 was 
significantly increased (p<1x10-8, OR=5.08) in patients (Figure 3a). However DQB1*03:02 
and DQB1*03:07, alleles linked with DRB1*04:01, DRB1*04:03, DRB1*04:04 and DRB1*04:05 
were not significantly increased in the patients because two of these alleles DRB1*04:01 and 
DRB1*04:05 were increased in the patients and the other two DR4 alleles DRB1*04:03 and 
DRB1*04:04 were significantly reduced in the patients. DQB1*03:01 (p<6x10-4, OR=0.27) and 
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Fig. 2. Peptide binding groove of the predisposing and protective HLA-DRB1 alleles 
showing positions 57 (P9), 74 (P4) and 86 (P1) for predisposing DRB1*03:01, DRB1*04:01 
and DRB1*04:05 and protective DRB1*07:01, DRB1*04:04 and DRB1*04:03  alleles. 
DQB1*05:03 (6x10-4, OR=0.28) were significantly reduced in the patients. Homozygosity of 
DQB1*02:01 was significantly (p<1x10-5, OR=5.4) increased in the patients (Figure 3b). 
DQB1*03:02 which was not significantly increased in the patients, showed a significant 
increase in heterozygous combination with DQB1*0201 (p<2x10-5, OR=34.16). In fact none of 
the controls had DQB1*0201/*0302 heterozygous combination. In a Swedish study, 
DQA1*0301/DQB1*0302 and heterozygous combinations of DQA1*0301/DQB1*0302 and 
DQA1*0201/DQB1*0501 have been shown to confer the highest susceptibility (Sanjeevi et al., 
1995).  
Some critical residues within the peptide binding sites of HLA-DQ beta chain have been 
proposed to play a crucial role in conferring predisposition to and protection from the 
diseases (Nepom & Kwok, 1998, Sheehy, 1992, Todd et al., 1987). Several studies have 
suggested that aspartic acid at DQ residue 57 confers protection while DQB1 alleles with 
alanine at that position (DQB1*02:01 and DQB1*03:02) and DQA1 with arginine at position 
52 (R52) confer susceptibility (Badenhoop et al., 1995, Chauffert et al., 1995, Todd et al., 1987). 
However, an individual can be either homozygous or heterozygous for alleles carrying 
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Fig. 3. Distribution of HLA-DQB1 alleles in T1D patients and controls. a shows DQB1*02:01 
was significantly increased and DQB1*03:01  and DQB1*05:03 were significantly reduced in 
T1D patients as compared to controls. b. Homozygous and heterozygous DQB1 alleles in 
T1D. Homozygous DQB1*02:01/*02:01 and heterozygous DQB1*02:01/*03:02  were 
significantly increased and DQB1*03:02/X  were significantly reduced in T1D patients as 
compared to controls (Rani et al., 2004). 
Asp57 in DQB1 or Arg52 in DQA1. Our in-depth investigation revealed that  when DR3 
homozygosity was considered along with codon 57 of DQB1 and codon 52 of DQA1, the 
only combination that was significantly increased in the patients group as compared to  
the controls was DRB1*03:01,03:01-DQB1*XX-DQA1*RR, suggesting that DRB1*03:01 
association is primary since the DQB1 and DQA1 alleles which are in linkage disequilibrium 
with DRB1*03:01 have non-Asp57 (DQB1*X) and Arg52 (DQA1*R), respectively(Rani et al., 
1999).  
3. Insulin linked polymorphic region in T1D (IDDM2)  
Insulin linked polymorphic region (IDDM2) consists of a highly polymorphic stretch of 14-
15 base pair repeats of DNA lying 365 bp upstream of the initiation of transcription of the 
insulin (INS) gene. IDDM2 has been shown to have a role in transcription of insulin in 
thymus. Several forms of IDDM2 have been reported based on the number of repeats (Bell et 
al., 1981, Kennedy et al., 1995). These INS-variable number of tandem repeats (VNTR) are 
divided into three different classes based on their sizes: class-I (26-63 repeats), Class II (about 
85 repeats) and class III (141-209 repeats) (Bell et al., 1982, Bennett et al., 1995, Rotwein et al., 
1986). T1D is associated with class I homozygosity (Bell et al., 1981, Bennett et al., 1995, 
Kennedy et al., 1995, Lucassen et al., 1993). We studied INS-VNTR Class-I and Class-III 
alleles based on typing for Insulin gene 1127 Pst I site (3’end) by PCR-RFLP as described by 
Pugliese et al (Pugliese et al., 1997) 
Table 1 shows the frequencies of Insulin VNTR in T1D patients and healthy controls. While 
the frequency of class-I VNTR was increased significantly in the patients, class-III VNTR was 
decreased in them as compared to the controls. However, when the genotypes were studied, 
class I homozygosity was considerably increased in the patients as compared to controls, 
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giving an Odds ratio of 7.8.  Class I, III heterozygosity was significantly reduced in the 
patients (Rani et al., 2004). 
 
INS-VNTR DIABETES CONTROLS p value OR 
 No. % No. %
Class I 108 98.2 85 89.47 0.008 6.35
Class III 64 58.2 87 91.57 2 X 10-8 0.13
Genotypes
Class I, I 46 41.8 8 8.42 2X10-8 7.8
Class I, III 62 56.4 77 81.05 10-5 0.301 
Class III, III 2 1.8 10 10.52 0.008 0.157 
Table 1. INS-VNTR allele frequencies and Genotype frequencies in T1D patients and 
controls.  
3.1 Simultaneous presence of predisposing HLA-DRB1 and INS-VNTR alleles  
MHC and VNTR are encoded on two different chromosomes. However, they may have 
integrated roles in manifestation of T1D due to the functional implications of these genes. 
So, we studied if simultaneous presence of the predisposing alleles of the two genes had any 
role to play in manifestation of T1D. 
Our investigation revealed that homozygous Class-I INS-VNTR along with homozygous or 
heterozygous DRB1*03:01 were significantly increased in the T1D patients (p<1x10-8) with a 
Relative Risk of 70.81 (Rani et al., 2004). In fact, none of the controls had homozygous Class-I 
INS-VNTR along with DRB1*03:01 in homozygous or heterozygous state. This combination 
gives a positive predictive value (PPV) of 100% with a specificity of 100% and sensitivity of 
32.63% since only 32.63% of the patients showed this combination. Since DRB1*03:01 
homozygosity is significantly increased in the patients, homozygous DRB1*03:01 and 
heterozygous DRB1*03:01 only with DRB1*04:01 and DRB1*04:05 along with heterozygous I, 
III-INS-VNTR may also be considered as predisposing since it gives a relative risk of 10.55 
(Rani et al., 2004).  
If we add all these predisposing combinations i.e. simultaneous presence of homozygous or 
heterozygous HLA-DRB1*03:01 along with homozygous (Class-I, I) or heterozygous (I, III)  
VNTR class-I and III,  50.53% of the patients as compared to only 1.4% of the controls had 
these combinations giving a relative risk of 48.67. This combination gives a PPV of 97.96% 
with a specificity of 98.6% and sensitivity of 50.5% since only 50.5% of the patients showed 
this combination. Thus, our results showed that: (1) homozygous or heterozygous 
DRB1*03:01 along with homozygous Class-I INS-VNTR and (2) homozygous DRB*03:01 and 
heterozygous DRB1*03:01 only with DRB1*04:01 or DRB1*04:05 with heterozygous Class-I/III 
INS-VNTR may be used to predict a pre-diabetic before the onset of the disease in North 
Indian high risk group (Rani et al., 2004). However, typing a larger cohort may be required 
to confirm such a major increase in risk.   
Pathogenesis of T1D is extremely complex. Significant association with HLA-DRB1*03:01 
and INS-VNTR Class-I may have functional implications. Increase in frequency of particular 
MHC allele suggests that these molecules may be preferentially presenting certain auto-
peptides to the T cells resulting in subsequent autoimmune responses. Studies on INS-
VNTR, however, have shown that class-III alleles are associated with 2 to 3 fold higher 
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mRNA levels of insulin than Class-I in thymii of fetuses, suggesting poor expression of 
thymic INS expression  resulting in poor thymic education for insulin in people with 
homozygous Class-I,I and class-I,III VNTRs resulting in break of tolerance in predisposed 
individuals. However, higher expression of insulin in the thymii of individuals with 
homozygous class-III, III may be able to facilitate immune tolerance induction, as a 
mechanism for dominant protective effect of Class-III alleles (Pugliese et al., 1997, Vafiadis et 
al., 1997).   
Our results are contrary to that of Veijola et al. (Veijola et al., 1995) on Finnish children who 
showed that both 5' and 3' INS loci showed an association with T1D in non-DR3/non-DR4 
patients (Veijola et al., 1995). However, in our studies only 9.47% of the non-DR3/DR4 
patients were homozygous for Class-I INS-VNTR as compared to 4.2% controls and this 
difference was not significant statistically. Julier et al. (Julier et al., 1991), on the other hand, 
had reported that the risk contributed by the INS region was increased in DR4-positive 
patients. Again, in our study only 6.32% of the patients as compared to 1.39% of controls 
had INS-VNTR class-I homozygosity with DRB1*04:01 and DRB1*04:05 alleles and this 
difference was not significant statistically. 
4. Cytokine genes 
Cytokines are the coordinators of the immune system that interact in integrated networks 
and functions of one cytokine may be modulated or substituted by another (Bidwell et al., 
1999). A cascade of cytokines are involved in pro-inflammatory auto-immune responses 
in T1D. Single nucleotide polymorphisms (SNPs) in different pro-inflammatory and anti-
inflammatory cytokine genes at certain defined regions have been shown to be associated 
with differential amount of their production (Asderakis et al., 2001, Awad et al., 1998, 
Bittar et al., 2006, Burzotta et al., 2001, Fishman et al., 1998, Louis et al., 1998, Pociot et al., 
1993). Pro-inflammatory cytokines and their integrated influences are known to regulate 
complex immune responses during autoimmune destruction of tissues (Rabinovitch, 
1994). Hence it is necessary that they are studied and analysed in context of each other 
and not in isolation from each other. We had reported for the first time the integration and 
interaction of TNF-  gene with other cytokine genes and HLA-DRB1 and B loci alleles 
(Kumar et al., 2007). 
We studied the cytokine gene polymorphism using XIIIth International Histocompatibility 
Workshop’s (IHWC, Heidelberg kit) and One lambda’s cytokine typing kits (Canoga Park, 
CA, USA) based on Polymerase Chain reaction (PCR) with sequence specific primers (PCR-
SSP). PCR-SSPs were done for IFN- (A+874T) (14), TNF- (G-308A) (15), IL-6 (G-174C) (9), IL-10 
(A-1082G, T-819C, C-592A) (16), and TGF1 (Tcdn10C, Gcdn25C) (11). T→C substitution in nucleotide 
29, codon 10 of the first exon of TGF1, changes the amino acid Leu → Pro. Similarly G→ C 
substitution in nucleotide 74, codon 25 of first exon of TGF1, changes the amino acid Arg 
→ Pro. However, since we are studying the SNPs in the two codons, we will refer to the 
SNPs in codons 10 and 25 hereafter. and not the resultant amino acids to avoid any 
confusion and to maintain consistency with the other SNPs.   
Our results showed that the high producing genotype of TNF--308GA and AA were 
significantly increased and low producing genotype GG was significantly reduced in T1D 
patients as compared to controls (p < 7 x10-6). None of the other cytokine genes showed any 
significant difference between the patients and controls.  
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4.1 Simultaneous presence of TNF- genotypes with IFN-, IL-6, IL-10 and TGF-1 
genotypes and haplotypes 
TNF-, IFN-, IL-10, IL-6 and TGF-1 genes are localized on different chromosomes. TNF- 
is encoded on chromosome 6p21.3, IFN- is encoded on 12q14, IL-10 is encoded on 1q31-q32, 
IL-6 is encoded on 7p21 and TGF-1 is encoded on 19q13.2. However, the products of these 
genes interact in integrated networks. Since only TNF- showed a significant association 
with T1D, we studied whether simultaneous presence of TNF- genotypes with different 
genotypes of the other cytokines in an individual could suggest an interaction between these 
cytokine genes. 
 
Other cytokines TNF-α GA/AA TNF-α GG 
Genotype / 
haplotype 
T1D 
No. 
(%) 
Controls
No. 
(%) 
p OR 
(95% CI) 
T1D 
No. 
(%) 
Controls
No. 
(%) 
p OR 
(95% CI) 
IFN-γ Int +874 N=235 N=128   N=235 N=128   
AA (L) 
41 
(17.4) 
9 (7.0) 0.003@ 
2.79 (1. 25-
6.42) 
46 (19.6) 44 (34.4) 0.001@ 
0.465 (0.28-
0.77) 
TA+TT (H) 
56 
(23.8) 
15 (11.07) 0.003@ 
2.39 (1.24-
4.66) 
92 (39.1) 60 (46. 9) 0.188 
0.729 (0.461-
1.15) 
IL-6 -174 N=235 N=127$   N=235 N=127$   
CC (L) 11 (4.7) 1 (0.78) 0.03# 
4.3 (1. 21-
14.56) 
14 (5.95) 8 (6.29) 0.531 
0.919 (0.357-
2.53) 
GG+GC (H) 
86 
(36.6) 
23 (18.1) 0.0001@ 
 2.61 
(1.5-4.56) 
124 
(52.75) 
95 (74.8) 0.000004@ 
0.76 (0.227-
0.621)  
IL-10 
Haplotypes* 
N=235 N=128   N=235 N=128   
Low secretor 
45 
(19.2) 
16 (12.7) 0.068 
1.65 (0.86-
3.22) 
77 
(32.76) 
57 (44.5) 0.03# 
0. 607 (0. 38-
0.96) 
High Secretor 
52 
(22.1) 
8 (6. 25) 0.0001@ 
4.26  (1.9-
10.1) 
61 
(25.95) 
47 (36.7) 0.04# 
0.6 (0.37-
0.98) 
TGF-β1 
Haplotypes* 
N=235 N=128   N=235 N=128   
Low secretor 8 (3.4) 1 (0.8) 0.11 
3.17 (0.87-
12.11) 
7 (2.98) 3 (2.3) 0.506 
1.17 (0.443-
3.23) 
High Secretor 
89 
(37.8) 
23 (18.0) 0.00004@ 
 2.8 (1.6- 
4.86) 
131 
(55.7) 
101 (78.9) 0.000006@ 
0. 336 (0.198-
0.568) 
N=Total number of samples studied,   $Number of  control samples studied for IL-6 were 127, one 
sample could not be typed due to PCR failure. TNF-α GA/AA have been combined as high secretor 
genotypes. 
# Corrected p value (pc) not significant, @ Corrected p value (pc) significant,  
*IL-10 : halpotype combinations -1082/-819/-590 : GCC,GCC; GCC,ACC; GCC,ATA= high secretors; 
ACC,ACC; ACC,ATA = Low secretors.  
TGF- β1 halpotype combinations Cdn10/Cdn25 : TG,TG; TG,CG; TG,CC; CG,CG =High secretors, 
CG,CC, CC,CC = Low secretors. 
Table 2. Simultaneous presence of TNF- genotypes with IFN-γ, IL-6, IL-10 and TGF-β1 
genotypes and haplotypes (Kumar et al., 2007). 
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Table 2 shows the simultaneous presence of high and low secreting genotypes of TNF-, 
along with IFN-, IL-6, IL-10 and TGF-1 genotypes and haplotypes. When IFN- was 
studied by itself, it did not show any significant difference between patients and controls. 
However, when studied in the context of TNF- -308G/A, both low and high secretor 
genotypes, IFN- (+874AA and TA+TT respectively) along with high secretor genotypes of 
TNF- -308 GA+AA were significantly increased in patients as compared to controls, 
suggesting its effect is rather neutral. However, low producer genotypes of TNF- -308GG 
along with low producer genotype of  IFN- +874 AA seems to be protective. Interestingly, 
66. 7% of the patients who had low producer genotype of TNF- -308GG had high producer 
genotype of  IFN- +874 TA+TT. Hence, in the absence of high secretor genotype of TNF-, 
IFN- may have a role in autoimmune destruction of pancreatic beta cells. IFN- acts 
singularly as well as synergistically with other inflammatory stimuli to induce NO 
production which can be cytotoxic and thus has been implicated in pathogenesis of certain 
autoimmune and inflammatory diseases (Mccartney-Francis et al., 1993).  
Similarly, promoter SNPs of IL-6 -174G/C did not show any significant difference between 
patients and controls, but when studied in the context of TNF- -308G/A, high producer 
genotypes, IL-6 -174 GG+GC (Fishman et al., 1998)  were increased in patients with TNF- -
308 GA+AA. Kristiansen and Mandrup-Poulsen (Kristiansen & Mandrup-Poulsen, 2005) 
have shown that IL-6 promotes islet inflammation but is unable to promote β-cell 
destruction for which other pro-inflammatory cytokines are needed. The other pro-
inflammatory cytokine playing a role in destruction β-cells in the present scenario could be 
 
HLA-B-DRB1-haplotypes Patients 
N=210 
Controls 
N=91. 
p OR (95% C.I.) 
 No* % No* %   
B*8-DRB1*03 69 32.85 3 3.3 10-8 
14.35  
(4.19 -37.93) 
B*8- Non DRB1*03 2 0.95 1 1.1 0.662 
0.865  
(0.498-1.5) 
B*50 – DRB1*03 41 19.5 3 3.3 6x10-5 
7.11  
(2.04-21.47) 
B*50 – Non-DRB1*03 6 2.86 4 4.4 0.355 
0.639  
(0.155-2.77) 
B*58 – DRB1*03 36 17.1 5 5.5 0.003 
3.55  
(1.27-10.72) 
B*58 – Non DRB1*03 3 1.4 8 8.8 0.003 
0.165  
(0.06-0.433) 
NonB8/B50/58-DRB1*03 35 16.7 6 6.6 0.01 
2.83  
(1.09-7.82) 
NonB8/B50/B58/non 
DRB1*03 
38 18.1 59 64.8 10-8 
0.12  
(0.06-0.216) 
* No. of patients /Controls with the haplotypes shown in the first column. 
Table 3. Comparison of HLA-B-DRB1 haplotypes showing significant association, between 
patients and controls (Kumar et al., 2007) 
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TNF- α in patients with GA and AA genotypes and IFN- in patients with TNF- GG 
genotype. High producer genotype IL-6 -174 GG+GC along with low producer genotype of 
TNF- -308GG seems to be protective.  
Different haplotypes of IL-10 based on SNPs in the promoter region have been shown to be 
associated with quantity of IL-10 production in-vitro (Asderakis et al., 2001, Stanilova et al., 
2006). The frequency of low producer haplotype of IL-10 ATA (haplotype with positions -
1082/-819/-590) has been shown to be increased in the adult onset patients in Japan, with no 
significant differences between T1D patients and controls (Ide et al., 2002). Reynier et al 
(Reynier et al., 2006) did not see any significant association  of IL-10-1082G/A with T1D in 
French population. However, they did observe a significant association of IL-10 -1082 
polymorphism to be associated with GAD and IA-2 antibody at clinical onset. In our study 
also, we did not observe any significant difference between TID patients and controls when 
IL-10 was studied by itself. However, simultaneous presence of high producer genotypes of 
TNF- -308 GA+AA and high producer haplotypes of IL-10 in the patients may have a role 
in recruitment of islet specific CD8+ T cells and thus may have a role in insulitis through 
ICAM-1 dependent pathway. In non-obese diabetic (NOD) mice (animal model for human 
Type 1 diabetes) pancreatic IL-10 has been shown to hyper-induce ICAM-1 expression on 
vascular endothelium. However, in the absence of ICAM-1, insulitis and diabetes could be 
prevented, thus providing evidence that IL-10 is sufficient to drive pathogenic autoimmune 
responses and accelerated diabetes via an ICAM-1 dependent pathway (Balasa et al., 2000). 
Presence of IL-10 during early stages of IDDM has also been shown to favor the generation 
of effector CD8+ T cells leading to accelerated diabetes in NOD mice (Balasa et al., 2000). 
Treatment of young mice with anti-TNF- and anti-IL-10  mAb has also been shown to 
prevent diabetes and insulitis (Lee et al., 1996, Yang et al., 1994). 
Similarly, when TGF-1 was studied by itself, no significant difference was observed between 
patients and controls. A significant increase of high producer haplotypes of TGF-1 with TNF-
 -308 GA+AA and a significant decrease of high producer haplotypes of TGF-1 with TNF- -
308GG in T1D patients as compared to controls was observed. These results show that 
different cytokines  work in concert with each other and may alter or modulate their functions 
depending on the milieu. TGF-1 has been shown to be an extremely potent chemotactic factor 
in-vitro which influences monocyte recruitment and accumulation via increased expression of 
α and β integrins (Wahl et al., 1993). It has been shown to rapidly and transiently up-regulate 
α-4 integrin dependent adhesion of leukocyte cell lines and peripheral blood lymphocytes 
(Bartolome et al., 2003). α-4 integrin, in turn, has been shown to play a prominent role in the 
spontaneous development of insulitis and diabetes in NOD mice (Yang et al., 1997). Increased 
levels of TGF-1 have been associated with destruction of pancreatic beta cells and 
pathogenesis of diabetic complications (Korpinen et al., 2001). Hence, in the presence of high 
secretors of TNF-, the high secretor genotypes of TGF-1 may have a role both in destruction 
of pancreatic beta cells as well as in migration of CD4+ and CD8+ T cells into the pancreas 
(Insulitis) through α-4 integrin, which act against pancreatic beta cells along with Nitric oxide 
mediated cytotoxicity. Under these circumstances, TGF-1 may not be able to arrest the pro-
inflammatory functions of TNF- and IFN-. 
So, our data provides circumstantial evidence justifying the presence of high secretor 
genotypes of TNF- -308GA and AA along with high secretor genotypes of IL-6, IL-10 and 
TGF-β1 and provide an immunogenetic basis for the autoimmune responses in T1D. The 
data suggest that the beta cell destruction in T1D may be mediated by both CD4+ T helper 
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cells and CD8+ cytotoxic T cells recruited through Integrins and ICAM-1 dependent 
pathways in the pancreas for which cytokine genes seem to play a pivotal role. 
4.2 TNF- α and HLA genes 
TNF- gene is very closely linked to the MHC. Deng et al (Deng et al., 1996) observed that 
the TNF- associations in Caucasians and Chinese of Taiwan, may be due to its being in 
linkage disequilibrium with DR3-DQB1*0201 haplotype. We too had observed DRB1*03:01, 
DRB1*04:01 and DRB1*04:05 to be associated with T1D in North Indians  (Rani et al., 2004). 
Hence, we wanted to study if the TNF- association was independent of these alleles or due 
to linkage disequilibrium (LD) between TNF- -308A and the predisposing DRB1 alleles. 
Interestingly,  the LD analysis showed that both TNF- -308A as well as TNF- -308G alleles 
are in LD with DRB1*03:01, the most predisposing HLA-DRB1 allele, suggesting that the 
effect of TNF- -308A is not because of its being in LD with HLA-DRB1*03:01, the 
predisposing MHC allele. 
Since TNF- locus is very closely linked to HLA-B locus, we also studied the alleles of B-
locus for a possibility of TNF- -308A allele being in LD with one of the B-locus alleles . 
Surprisingly we observed LD between TNF- -308G with B*08 and  TNF- -308A allele with 
HLA B*50:01 and B*58:01. All the three B-locus alleles B*08:01, B*50:01 and B*58:01 were in 
linkage disequilibrium with DRB1*03:01 (Table 3). Because of HLA-B*08 being in LD with 
TNF- -308G, B*08:01-DRB1*03:01 haplotype was also in LD with TNF- -308G (Table 4).  
 
HLA-B-TNF-α-DRB1-
haplotypes 
Number of haplotypes 
observed 2N=418 
Haplotype 
frequencies 
Dabc# 
B*8- TNF-α  -308A-DRB1*03  19 0.045 -0.013 
B*8- TNF-α -308G-DRB1*03  75 0.179 0.015 
B*50- TNF-α  -308A-DRB1*03  42 0.1 0.0329 
B*50- TNF-α -308G-DRB1*03  32 0.076 -0.0023 
B*58- TNF-α  -308A-DRB1*03  33 0.079 0.0141 
B*58- TNF-α  -308G-DRB1*03  28 0.067 -0.0032 
Table 4. Linkage disequilibrium analysis of HLA-B- TNF-α -DRB1 haplotypes prevalent in  
T1D patients from North India (Kumar et al., 2007). 
However, B*50:01-DRB1*03:01 and B*58:01-DRB1*03:01 haplotypes were in LD with TNF- -
308A allele. We observed 48.8 % of the patients had B*08/non-B*08/non-B*50:01/non-
B*58:01-TNF--308G-DRB1*03:01 haplotypes as compared to 34 % with B*50:01/ B*58:01- 
TNF- -308A-DRB1*03:01 haplotypes. With this in-depth analysis, it becomes clear that the 
effect of TNF- -308A allele is not because of its being in LD with DRB1*03:01, B*08:01, 
B*50:01 or B*58:01, but due its functional implications and its integrated effect with other 
cytokines. In conclusion,  while the MHC may be  involved in auto-antigen presentation, 
TNF- alpha  and other cytokines play an integrated role in destruction of the pancreatic beta 
cells though enrichment and recruitment of autoantigen specific CD4+ and CD8+ T cells 
which have immunogenetic bases (Figure 6). 
5. Vitamin D receptor 
Vitamin D Receptor (VDR) is a ligand dependent transcription factor that belongs to the 
super family of the Nuclear Hormone Receptors (Evans, 1988). The ligand for VDR is 
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Vitamin D3 i.e., 1,25-(OH)2D3 which mediates its biological actions through VDR. When 
1,25-(OH)2D3 binds to VDR, it induces conformational changes in VDR promoting its hetero-
dimerization with Retinoid X Receptor (RXR), followed by translocation of this complex into 
the nucleus. The RXR-VDR heterodimer in turn binds to the vitamin D3 responsive elements 
(VDRE) in promoter regions of vitamin D responsive genes (Boonstra et al., 2001). This 
results in the regulatory function of Vitamin D3. In the absence of classical responsive 
elements, 1,25-(OH)2D3 may controls the expression of some genes like cytokine genes by 
targeting inducible transcription factors like NFAT in IL-2 in a sequence specific manner 
(Takeuchi et al., 1998). 1,25-(OH)2D3 has been shown to have an important immuno-
modulatory role since it represses transcription of Th1 cytokines like  IL-2 (Alroy et al., 1995, 
Bhalla et al., 1984), IFN-γ (Cippitelli & Santoni, 1998) and IL-12 (D'ambrosio et al., 1998) and 
up regulates the production of Th2 cytokines IL-4 and TGF-β1 (Cantorna et al., 1998). It has 
been shown to enhance the development of TH2 cells via a direct effect on naive CD4+ cells 
(Boonstra et al., 2001). Besides, 1,25-(OH)2D3 has also been shown to modulate the 
expression of HLA class-II alleles on monocytes and human bone cells (Rigby et al., 1990, 
Skjodt et al., 1990)  
Studies have shown that administration of Vitamin D3 in NOD mice,  before the onset of 
Insulitis, can effectively prevent the disease progression. However, when administered after 
the establishment of insulitis, vitamin D3 was not as effective. Similarly, in  humans too, 
vitamin D supplementation in early childhood has been shown to reduce the incidence of T1D 
(Hypponen et al., 2001, Jones et al., 1998). Since 1,25-(OH)2D3 mediatesi its effect through  VDR, 
we studied the VDR gene polymorphisms and their interaction with the most predisposing 
MHC alleles to investigate their role, if any, in the pathophysiology of T1D.  
The VDR SNPs studied include the T>C SNP in exon2 initiation codon detected with FokI 
restriction enzyme (Gross et al., 1996), the A>G SNP detected with BsmI (Morrison et al., 
1992) and G>T SNP detected with ApaI (Faraco et al., 1989) located in Intron  8, and a silent 
C>T SNP (Durrin et al., 1999) detected with TaqI, located in Exon 9. These SNPS were 
studied using PCR amplification and restriction digestion by the aforesaid enzymes as 
described earlier (Faraco et al., 1989, Hustmyer et al., 1993). We also studied the interaction 
between VDR alleles and predisposing HLA alleles using LD based statistics (Zhao et al., 
2006) and subsequently sequenced the promoter region of the predisposing MHC allele to 
detect the VDRE sequence which has been shown to modulate the expression of the HLA 
alleles (Ramagopalan et al., 2009), suggesting the functional implications of the statistically 
significant interaction (Israni et al., 2009). We further provided documentary evidence that 
expression of HLA class-II molecules was being modulated by vitamin D3. 
5.1 VDR FokI,  BsmI, ApaI and TaqI genotypes and haplotypes in T1D patients 
While there were no significant differences in the genotypes of ApaI and TaqI in patients and 
controls. FokI ‘ff’ was significantly increased in the patient group as compared to controls 
and BsmI ‘bb’ was significantly decreased in the patient group. However, these differences 
did not remain significant after Boneferroni’s correction (Israni et al., 2009). 
Haplotype analysis was carried out for the four restriction sites studied in the VDR gene in 
patients and controls using SHEsis program (http://202.120.7.14/analysis/myAnalysis.php) 
(Shi & He, 2005). Additionally, Famhap (http://famhap.meb.uni-bonn.de ) was used to 
confim the frequencies of the haplotypes. Haplotype FBAt and fBAT were significantly 
increased in T1D patients and fBAt was significantly reduced in them as compared to controls.  
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5.2 Gene to gene interaction of VDR haplotypes with predisposing HLA alleles 
Simulateneous presence of different VDR haplotypes along with the predisposing HLA 
alleles was studied in patients. Interestingly, simultaneous presence of haplotypes FBAT and 
FbaT along with the predisposing DRB1 alleles was significantly increased while the same 
haplotypes were protective when associated with non-predisposing alleles of DRB1. Similar 
results were obtained with other haplotypes like FBAt, fBAT and fbaT in association with the 
predisposing HLA-DRB1 alleles (Israni et al., 2009). 
To study the interaction between two unlinked loci i.e., VDR and the predisposing HLA-
DRB1 alleles, we used LD based statistics as described by Zhao et al (Zhao et al., 2006). The 
analysis revealed that F and T alleles in the exons 2 and 9 for FokI and TaqI restriction sites 
respectively showed significant interactions with predisposing HLA-DRB1 allele DRB1*03:01 
(Israni et al., 2009).  
 
 
 
Fig. 4. HLA- DRB1*03:01 promoter sequence from 3 subjects suffering from T1D and 3 
normal healthy individuals homozygous for DRB1*03:01.  Important regulatory elements 
like S-box, X-box, Y-box, CCAAY-box, TATA-box and VDRE are highlighted. Star (*) in the 
last row shows homology and dots (.) shows nucleotide substitution in one or more samples 
at that particular site and dashes(-) represent gaps inserted to maximize the homology. 
(Israni et al., 2009).  
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5.3 Sequence analysis of HLA DRB1*0301 promoter region 
Amongst the predisposing HLA-DRB1 alleles, majority of the patients (85.9%) had 
DRB1*03:01. Thus, we sought to look for the  VDRE in the promoter region of the allele. The 
promoter regions of 3 T1D subjects and 3 healthy controls homozygous for HLA-DRB1*03:01 
were amplified and sequenced to determine the VDRE variants in the North Indian 
population. Sequences were aligned using ClustalW2, and the presence of a VDRE was 
confirmed in-silico using JASPAR_CORE version 3.0 database using default conditions 
(Sandelin et al., 2004). Figure 4 shows the HLA- DRB1*03:01 promoter sequences showing 
the localization of vitamin D response element (VDRE) in the promoter region of HLA-
DRB1*0301 from the 6 subjects.  
Interestingly, the alignment showed exactly the same sequence of VDRE in the promoter 
region of HLA-DRB1*03:01 which has been shown to influence the expression of HLA allele 
DRB1*15:01 by Ramagopalan et al (Ramagopalan et al., 2009) suggesting the bases for 
interaction of VDR with HLA-DRB1*03:01 
5.4 Altered expression of HLA-DRB1*03:01 by 1,25-(OH)2D3  (Calcitriol) 
5.4.1 Flow cytometry 
To study if vitamin D3 administartion would alter the expression of MHC class-II, we 
stimulated HLA-DRB1*03:01 homozygous B-lymphoblastoid cell (B-LCL) line VAVY 
(International Histocompatibility Workshop cell line Number IHW09023) with 100nM of 
calcitriol (Sigma) for 24 hours and stained with anti-HLA DR-PE antibody (BD Biosciences) 
and acquired on BD-LSR to study the expression of HLA-DR on stimulated and 
unstimulated B-LCL The data was analysed using WinMDI 2.9 software. The results showed 
significantly higher expression of HLA-DR in the B-LCL stimulated with calcitriol as 
compared to the unstimulated one (Figure 5A and B). 
5.4.2 Real time PCR 
We also studied the levels of transcripts for HLA-DRB1 in B-LCL VAVY after 24 hour 
stimulation with calcitriol and compared it to unstimulated B-LCL  using real time PCR. The 
data shows 1.89 fold increase in the HLA-DRB1 transcripts from B-LCL stimulated with 
calcitriol as compared to the unstimulated one. These results were confirmed on perpheral 
blood mononuclear cells (PBMCs) derived from a normal healthy control homozygous for 
HLA-DRB1*03:01. 
Our results showed enhanced expression of HLA-DR on the B-LCLs stimulated with 
calcitriol as compared to the unstimulated one confirming that indeed the interaction of 
VDR with HLA-DRB1*03:01 is occurring through the VDRE present in the promoter region 
of the gene. Based on the earlier studies and the present data one can speculate that in the 
absence of required amount of Vitamin D in early life in the predisposed individuals with 
HLA-DRB1*03:01, the expression of the allele may be impaired in the thymus (Ramagopalan 
et al., 2009) resulting in escape from thymic deletion of autoreactive T cells leading to T1D 
manifestations.  
6. Conclusions 
Our studies show that simultaneous presence of DRB1*03:01 along with homozygous INS-
VNTR class-I was significantly increased ( p < 10-8) in T1D patients, giving a relative risk of 
70.81 (Rani et al., 2004). INS-VNTR class-I has been shown to be associated with lower 
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Fig. 5. Flow cytometric analysis of HLA-DR expression.  A: Histogram of HLA-DR-PE 
staining of B-LCL-VAVY cells treated with and without 100nM calcitriol. The figure shows 
enhanced expression of HLA-DR in stimulated B-LCL as compared to unstimulated one.  B: 
VAVY cells show a significant  increase in surface HLA-DR expression as determined by the 
geometric mean flurescence intensity of  antibody staining (Israni et al., 2009). 
expression of Insulin in thymii of fetuses as compared to Class-III alleles (Pugliese et al., 
1997, Vafiadis et al., 1997) which may be responsible for poor thymic education for insulin 
resulting in autoimmunity against pancreatic beta cells. Our studies provide additional 
evidence based on the statistically significant interaction between the predisposing HLA 
allele and high producer alleles of VDR which may be detrimental for the manifestation of 
T1D in the absence of 1,25-(OH)2D3 in early childhood and/or in-utero and this interaction is 
mediated by VDRE present in the promoter region of DRB1*03:01(Israni et al., 2009). With 
poor thymic education for insulin and HLA-DRB1*03:01 protein, environmental factors like 
viral infections, vitamin D deficiency and some milk proteins may be involved in initiation 
of the autoimmune responses against the pancreatic beta cells. While HLA class-II molecules 
may be involved in auto-antigen presentation to T helper cells, higher producing genotypes 
of pro-inflammatory cytokines like IFN-gamma and TNF-alpha may be involved in enhancing 
the cell mediated immune responses through proliferation of CD4+ and CD8+ T cells, while 
higher producing genotypes of IL-10 and TGF-beta may have a role in recruitment of these 
autoreactive T cells in the pancreas through ICAM-1 and Integerin dependent pathways. 
Final destruction of pancreatic beta cells may occur through CD4+ and CD8+ T cells and 
nitric oxide production since IFN- may act singularly as well as synergistically with other 
inflammatory stimuli to induce NO production which can be cytotoxic and thus may have a 
role in pathogenesis of T1D (Figure 6). Future studies should focus on developing 
approaches to inhibit autoimmunity before the onset of the disease. 
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Fig. 6. Conclusions of our studies. Predisposing genetic factors like MHC, INS-VNTR and 
VDR may be involved in poor thymic education for insulin and HLA-DRB1*03:01 protein 
resulting in recognition of self proteins as non-self by T cells . These genetic factors along 
with environmental factors like viral infections, vitamin D deficiency and some milk 
proteins may be involved in initiation of the autoimmune responses against the pancreatic 
beta cells. While HLA class-II molecules may be involved in auto-antigen presentation to T 
helper cells, higher producing genotypes of pro-inflammatory cytokines like IFN-γ and TNF-
α may be involved in the cell mediated immune responses. Higher producing genotypes of 
IL-10 and TGF-beta,  may have a role in recruitment of the autoreactive CD4+ and CD8+ T 
cells in the pancreas through ICAM-1 and Integerin dependent pathways respectively. Final 
destruction of pancreatic beta cells may occur through CD4+ and CD8+ T cells and nitric 
oxide production since IFN- may act singularly as well as synergistically with other 
inflammatory stimuli to induce NO production which can be cytotoxic and thus may have a 
role in pathogenesis of T1D. 
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